LETTURA A TEMA Fibrillazione Atriale: Stato dell’Arte Prof. Luigi Padeletti Presenta: Saverio Iacopino Sant ’ Anna Hospital Catanzaro.

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information
Advertisements

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin.
The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.
for internal use only Evidence Based Medicine The Need to Avoid Unnecessary Ventricular Stimulation.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Can we prevent stent restenosis after coronary stent implantation
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Treatment of Heart Failure: Beyond Medical Therapy
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Prof. C. Moro, Madrid Non antiarrhythmic drugs for AF.
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Target Study Cardiac resynchronization therapy (CRT) is an established treatment for advanced heart failure symptoms, impaired LV systolic function, and.
Integrating Monitoring into the Infrastructure and Workflow of Routine Practice Philip B. Adamson, MD Associate Professor of Physiology Director, The Heart.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Spinal Cord Stimulation for Heart Failure Stuart P. Rosenberg, M.S. Senior Manager, Neuromodulation Research Implantable Electronic Systems Division St.
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
for internal use only How Works for internal use only Mitral valve closure can be estimated by measuring the interatrial conduction time (P-wave duration)
Journal Club Deephak Swaminath. Journal Incidence and predictors of right ventricularpacing- induced cardiomyopathy Shaan Khurshid,MD,* Andrew E.Epstein,MD,FHRS,*
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Natural History of Heart Failure
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
Rhythm and Rate Control for Atrial Fibrillation Tom Wallace, MD Cardiac Electrophysiology CHI St. Vincent Heart Clinic Arkansas.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Date of download: 6/1/2016 From: Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure Ann Intern Med. 2004;141(5):
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and efficacy of advanced atrial pacing therapies.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.
Alireza Heidari Bakavoli, MD. Cardiology department Qaem medical center Mashhad University of Medical Science Role of ICD and CRT devices in Heart failure.
Cardiac-Resynchronization in Moderate Heart Failure Christopher Hughes PA-S Pacific University School of Physician Assistant Studies, Hillsboro, OR USA.
RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Remote Monitoring of Implantable Cardioverter-Defibrillators:
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Reactive ATP and MINERVA
C. ACC/AHA/ESC guidelines Role of anticoagulant therapy in AF
Optimal Pacing for Right Ventricular and Biventricular Devices
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD  Heart Rhythm 
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Mintu P. Turakhia et al. JACEP 2016;2:
Impedence-guided management
Mahesh Anantha Narayanan et al. JACEP 2017;3:
Volume 12, Issue 8, Pages (August 2015)
Basic troubleshooting for CRTs
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep
European Heart Journal Advance Access
Jeffrey Senfield et al. JACEP 2017;3:
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

LETTURA A TEMA Fibrillazione Atriale: Stato dell’Arte Prof. Luigi Padeletti Presenta: Saverio Iacopino Sant ’ Anna Hospital Catanzaro

Network for person: Padeletti, Luigi

HF and AF are “ emerging epidemics ”

The interaction between AF and HF means that neither can be treated optimally without treating both HF AF promotes aggravates

Ventricular resynchronization and atrial pacing (algorithms, atrial resynchronization) may be considered a major revolution in treating AF and HF by electrical stimulation

Primary outcome: device-classified AT/AF frequency Secondary outcomes: device-classified AT/AF burden and PAC frequency Padeletti et al. JCE. 2003

Long-term Reduction of AT Recurrences in Patients Paced for BT-SND In a long-term observation on BT-SND patients, a significant decrease of AT related hospitalizations and increase of mean AT cycle length were measured. These data suggest that rhythm control therapies may induce an inversion of AT progression. Padeletti et al. HR. 2005

MASCOT Trial Multicenter, single-blind, randomized, parallel study evaluating the safety and efficacy of a specific AOP algorithm (AF Suppression™, St Jude Medical, Sylmar, CA) in CRT patients. After successful CRT device implantation, and before hospital discharge, the patients were randomly assigned to AOP ON versus OFF for the duration of follow-up. Padeletti et al. AHJ. 2008

MASCOT Trial: Incidence of Permanent AF

Padeletti et al. AHJ MASCOT Trial: Mortality

The two options to treat AF are either rhythm control defined as the strategy to restore and maintain sinus rhythm or rate control defined as the strategy to maintain the patient in AF and avoid too fast and too slow ventricular rates….. Padeletti L. et al. EHJ 2007